EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Tetrahydroberberine Suppresses Autophagy and Mitigates Doxorubicin‐Induced Ferroptosis in Hepatic Cells via cAMP ‐Epac1 Activation

Cheng Teng, Mo Chen, Ying Zhao, Song Hu, Linghui Kong, Yan Huang, Shunv Cai, Xiaoyan Zhu, Pengxiang Wang, Pingbo Xu

Phytotherapy Research · 2026-11-02

DOI: 10.1002/ptr.70500 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT This study investigated the hepatoprotective mechanism of tetrahydroberberine (THB) against doxorubicin (DOX)‐induced liver injury. Using DOX‐induced drug‐induced liver injury (DILI) mouse models and AML12 hepatocytes, THB significantly reduced serum ALT/AST levels, alleviated hepatic pathological damage, and suppressed autophagic flux and ferroptosis. Mechanistically, THB activated the cAMP‐Epac1 axis by directly binding Epac1, stabilizing FTH1 and upregulating GPX4, thereby blocking the crosstalk between ferritinophagy and ferroptosis. Network pharmacology suggested the cAMP pathway, and experimental validation identified Epac1 as the functional target. These mechanisms were validated using ESI‐09, rapamycin, 3‐MA, CETSA, and molecular docking. This study is the first to elucidate THB's hepatoprotective mechanism via the cAMP‐Epac1/FTH1/GPX4 pathway, offering a natural product‐based strategy for chemotherapy‐associated liver injury.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →